Skip to main content

Table 1 Baseline characteristics

From: Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer

 

PR + 

PR-

 
 

N

%

N

%

P

PR

 Positive

123,751

100.0

0

0.0

 

 Negative

0

0.0

12,769

100.0

 

Age

    

 < 0.001

  < 50 years

27,107

20.8

1155

8.6

 

 50 years or older

103,242

79.2

12,324

91.4

 

Race

    

 < 0.001

 Non-Hispanic White

106,157

81.4

10,744

79.7

 

 Hispanic White

7437

5.7

734

5.4

 

 Black

9686

7.4

1352

10.0

 

 Asian/Pacific Islander

4946

3.8

447

3.3

 

 Other

1064

0.8

96

0.7

 

 Not available

1059

0.8

106

0.8

 

Facility

    

 < 0.001

 Nonacademic

82,586

63.4

8612

63.9

 

 Academic

44,100

33.8

4643

34.4

 

 Not available

3663

2.8

224

1.7

 

Insurance

    

 < 0.001

 None

1551

1.2

179

1.3

 

 Private

79,056

60.6

7181

53.3

 

 Government

48,434

37.2

5993

44.5

 

 Not available

1308

1.0

126

0.9

 

Income

    

0.01

 Above median

75,920

58.2

7802

57.9

 

 Below median

35,120

26.9

3767

27.9

 

 Not available

19,309

14.8

1910

14.2

 

Education

    

 < 0.001

 Above median

70,707

54.2

7175

53.2

 

 Below median

40,507

31.1

4415

32.8

 

 Not available

19,135

14.7

1889

14.0

 

CDS

    

 < 0.001

 0

110,215

84.6

11,207

83.1

 

 1

16,208

12.4

1824

13.5

 

 2 + 

3926

3.0

448

3.3

 

Year

    

0.001

 Median

2014

 

2014

  

 IQR

2012–2016

2012–2016

 

Histology

    

 < 0.001

 Ductal or lobular carcinoma

111,903

85.8

11,764

87.3

 

 Other

18,446

14.2

1715

12.7

 

T staging

    

 < 0.001

 1

97,532

74.8

9631

71.5

 

 2

31,013

23.8

3621

26.9

 

 3

1804

1.4

227

1.7

 

N staging

    

 < 0.001

 0

110,421

84.7

11,897

88.3

 

 1a

19,928

15.3

1582

11.7

 

Grade

    

 < 0.001

 1

37,224

28.6

2871

21.3

 

 2

70,043

53.7

6533

48.5

 

 3

18,379

14.1

3563

26.4

 

 Other

58

0.0

21

0.2

 

 Not available

4645

3.6

491

3.6

 

RS

    

 < 0.001

 0–15

68,683

52.7

1925

14.3

 

 16–25

46,723

35.8

5394

40.0

 

  > 25

14,943

11.5

6160

45.7

 

LVSI

    

 < 0.001

 No

99,783

76.6

10,446

77.5

 

 Yes

16,081

12.3

1526

11.3

 

 Not available

14,485

11.1

1507

11.2

 

Chemotherapy

   

 < 0.001

 No

105,902

81.2

7435

55.2

 

 Yes

24,447

18.8

6044

44.8

 

Radiation

    

0.36

 No

40,291

30.9

4243

31.5

 

 Yes

88,630

68.0

9094

67.5

 

 Not available

1428

1.1

142

1.1

 

Surgery

    

0.56

 Lumpectomy

88,283

67.7

9161

68.0

 

 Mastectomy

42,039

32.3

4314

32.0

 

 Other

27

0.0

4

0.0

 

Margin

    

0.02

 Negative

126,053

96.7

12,990

96.4

 

 Positive

3856

3.0

451

3.3

 

 Not available

440

0.3

38

0.3

 
  1. PR Progesterone receptor, N Number, CDS Charlson-Deyo comorbidity score, IQR Interquartile range, RS 21-gene recurrence score, LVSI Lymphovascular space invasion